United Therapeutics reported that its second Phase III trial in idiopathic pulmonary fibrosis (IPF) met endpoints for Tyvaso (treprostinil), strengthening the company’s case for a supplemental NDA with an eye toward priority review. The company framed the Phase III results as positioning for a commercial ramp in 2027. In the study, Tyvaso showed superiority over placebo in change of absolute forced vital capacity and reduced risk of clinical worsening, while safety was described as well-tolerated. Separately, Viridian Therapeutics disclosed top-line Phase III results for elegrobart in active thyroid eye disease (TED), with the trial meeting its primary endpoint proptosis responder rate (PRR) versus placebo. Shares reacted negatively to the broader dataset and the open question of competitive positioning against Tepezza.